The FDA has approved Bayer’s Gadavist injection for use with MRI in pediatric patients younger than 2.
The U.S. Food and Drug Administration (FDA) has approved the first gadolinium-based MRI contrast agent for pediatric patients younger than age 2, according to Bayer HealthCare.
Gadavist (gadobutrol) has been indicated to detect and visualize areas with disrupted blood brain barrier and/or abnormal vascularity of the central nervous system, according to Bayer, who manufactures the agent.
The approval grants expanded use to Gadavist, which was first approved in 2011 for use in patient populations older than age 2. The FDA granted the expanded use after a study showed that the pharmacokinetic (PK) and safety profiles in pediatric patients younger than age 2 were similar to that of older children and adults at a standard dose (0.1 mmol/kg), Bayer announced. Gadavist was also approved in June 2014 for MRI of the breast to assess presence and extent of malignant breast disease.
“Until this study, there were limited data regarding the use of gadolinium-based contrast agents in pediatric patients younger than 2 years of age, and there has been a significant need to better understand how they work in our youngest patients,” Dr. Ravi Bhargava, study investigator and pediatric radiologist, University of Alberta, Edmonton, Canada, said in a release.
Deep Learning Model with DCE-MRI May Help Predict Proliferative Hepatocellular Carcinoma
May 20th 2024Incorporating dynamic contrast-enhanced MRI, a deep learning model demonstrated a 20 percent higher AUC in external validation testing than clinical factors alone and over a 17 percent higher AUC than radiological factors alone in predicting proliferative hepatocellular carcinoma (HCC).
ACR Collaborative Model Achieves 20 Percent Improvement in PI-QUAL Scores for Prostate MRI
May 9th 2024Using a learning network model to discuss challenges and share insights among radiology departments from five different organizations, researchers noted that 87 percent of audited prostate MRI exams had PI-QUAL scores > 4 at the conclusion of the collaborative program.
MRI-Based Deep Learning Algorithm Shows Comparable Detection of csPCa to Radiologists
May 8th 2024In a study involving over 1,000 visible prostate lesions on biparametric MRI, a deep learning algorithm detected 96 percent of clinically significant prostate cancer (csPCa) in comparison to a 98 percent detection rate for an expert genitourinary radiologist.